Sánchez FER, Carpinteyro EU, Erazo FMA, Sánchez BC

Language: Spanish
References: 15
Page: 213-216
PDF size: 289.36 Kb.

ABSTRACT

Background: Breast cancer is the most frequent neoplasia in the female sex. The number of new cases is 124.8 per 100,000 women per year, and the number of deaths is 21.9 per 100,000 women per year. Dissection of the sentinel lymph node has become a standard procedure in the management of early-stage breast cancer; it is a simple technique that uses subdermal or peri-tumoral injection of blue dye and/or radioactive isotope to identify the first lymph node draining the primary tumor. Patent blue V is a coloring agent used to identify this sentinel lymph node. Clinical cases: We report three cases of skin and fat necrosis in female patients with breast cancer who underwent sentinel lymph node biopsy localization using peri-tumoral injection of patent blue V dye. Discussion: The use of this dye can be associated with a number of local complications due to its tissue reactive properties. Conclusion: Subdermal injection of patent blue V dye is safe and effective for sentinel lymph node localization.

REFERENCES

1. Kohler BA, Sherman RL, Howlander N, Jemal A, Ryerson AB, Henry KA et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015; 107 (6): 1-25.

2. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V et al. Sentinel lymph-node biopsy as a staging procedure in breast cancer: update of a randomised control study. Lancet Oncol. 2006; 7: 983-990.

3. Cortés FH, Colomer BR. Tratado de oncología. Sección I. En: Cortés Funes H, Colomer Bosch R, editores. Cáncer de mama. 4.a ed. Barcelona: Publicaciones Permanyer; 2009. pp. 829-841.

4. De Cicco C, Cremonesi M, Lum A, Bartolomei M, Grana C, Prisco G et al. Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med. 1998; 39: 2080-2084.

5. Mokbel K, Mostafa A. The role of subareolar blue dye in identifying the sentinel node in patients with invasive breast cancer. Curr Med Res Opin. 2001; 17: 93-95.

6. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994; 220: 391-398.

7. Cimmino VM, Brown AC, Szocik JF, Pass HA, Moline S, De SK et al. Allergic reactions to isosulfan blue during sentinel node biopsy —a common event. Surgery. 2001; 130: 439-442.

8. Simmons RM, Smith SM, Osborne MP. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Breast J. 2001; 7: 181-183.

9. Stradling B, Aranha G, Gabram S. Adverse skin lesions after methylene blue injections for sentinel lymph node localization. Am J Surg. 2002; 184: 350-352.

10. Singh-Ranger G, Mokbel K. Capsular contraction following immediate reconstructive surgery for breast cancer. An association with methylene blue dye. Int Semin Surg Oncol. 2004; 11: 1-3.

11. Borgstein PJ, Meijer S, Pijpers R. Intradermal blue dye to identify the sentinel lymph node in breast cancer. Lancet. 1997; 349: 1668-1669.

12. Govaert GA, Oostenbroek RJ, Plaisier PW. Prolonged skin staining after intradermal use of patent blue in sentinel lymph node biopsy for breast cancer. Eur J Surg Oncol. 2005; 31: 373-375.

13. O’Morchoe CC, O’Morchoe PJ. Differences in lymphatic and blood capillary permeability: ultrastructural-functional correlations. Lymphology. 1987; 20 (4): 205-209.

14. Mostafa A, Carpenter R. Anaphylaxis to patent blue dye during sentinel lymph node biopsy for breast cancer. Eur J Surg Oncol. 2001; 27: 610.

15. Zengel B, Yararbas U, Sirinocak A, Ozkok G, Denecli AG, Postaci H, et al. Sentinel lymph node biopsy in breast cancer: review on various methodological approaches. Tumori. 2013; 99 (2): 149-153.